Similar impacts of setmelanotide treatment on HRQOL and hyperphagia burden have also been reported in pediatric and adult patients with other rare genetic diseases of obesity, including POMC and LEPR deficiency, highlighting the clinical utility of setmelanotide for HRQOL in patients with rare genetic diseases of obesity. Here, LEPR is linked to obesity due to melanocortin 4 receptor deficiency.